<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143857</url>
  </required_header>
  <id_info>
    <org_study_id>810580</org_study_id>
    <secondary_id>K01DA025073</secondary_id>
    <nct_id>NCT01143857</nct_id>
  </id_info>
  <brief_title>Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement</brief_title>
  <official_title>Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Plebani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine use, abuse and dependence is a public health problem that is directly responsible for&#xD;
      hundreds of billions of dollars in health care expenditures per year. Relapse rates to&#xD;
      cocaine use are high, creating a pressing need to develop effective therapies for cocaine&#xD;
      dependence. The proposed research will focus on investigating the determinants and&#xD;
      consequences of cocaine dependence via measurement of physiological, behavioral and&#xD;
      subjective effects of acute doses of cocaine in healthy non-drug dependent human volunteers&#xD;
      in the laboratory, and through examination of the effects of pharmacotherapies on the above&#xD;
      effects of cocaine. This study will examine cocaine-derived reinforcement under week-long&#xD;
      sub-chronic varenicline (Chantix) dosing, and under placebo conditions. The study is a&#xD;
      within-subjects crossover design using 24 subjects. Subjects will be screened and consented&#xD;
      into the study at the Treatment Research Center (TRC). Study visits where behavioral and&#xD;
      physiological outcome data will be obtained will be conducted at the Clinical and&#xD;
      Translational Research Center (CTRC) of the Hospital of the University of Pennsylvania.&#xD;
      Subjects will be outpatients for this trial, with CTRC sessions scheduled at least one week&#xD;
      apart.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Varenicline's impact on reinforcing effects of cocaine</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary aim of this study is to examine what impact sub-chronic dosing with varenicline has on the subjective and reinforcing effects of cocaine and on cocaine self-administration in cocaine experienced individuals.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline 2.0 mg/day or Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Males and females, 18 to 60 years old.&#xD;
&#xD;
          2. Recreational users of cocaine reporting at least six instances of cocaine use in the&#xD;
             past 12 months and at least one use in the past 30 days.&#xD;
&#xD;
          3. Live within a commutable distance of the Treatment Research Center (TRC) at the&#xD;
             Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to&#xD;
             be a distance within the service area of Septa, within an hour drive, or a distance&#xD;
             that both the patient and Principal Investigator (PI) find acceptable.&#xD;
&#xD;
          4. Understands and signs the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current DSM-IV diagnosis of any psychoactive substance dependence other than nicotine&#xD;
             dependence, as determined by the Structured Clinical Interview for the DSM (SCID).&#xD;
&#xD;
          2. Current severe psychiatric symptoms (e.g., psychosis, dementia, suicidal or homicidal&#xD;
             ideation, mania or depression requiring anti-depressant therapy) as diagnosed using&#xD;
             the SCID, the Hamilton Anxiety Rating Scale (Ham A), and Hamilton Ration Scale for&#xD;
             Depression (HAM-D).&#xD;
&#xD;
          3. Individuals scoring &gt; 10 on the Hamilton Rating Scale for Depression (HAM-D).&#xD;
&#xD;
          4. Use of any investigational medication within the past 30 days.&#xD;
&#xD;
          5. Concomitant treatment with psychotropic medications.&#xD;
&#xD;
          6. Concomitant use of any one of the following drugs or classes of drugs:&#xD;
&#xD;
               -  Reserpine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  theophylline,&#xD;
&#xD;
               -  trimethoprim,&#xD;
&#xD;
               -  cimetidine,&#xD;
&#xD;
               -  haloperidol,&#xD;
&#xD;
               -  benzodiazepines, or&#xD;
&#xD;
               -  antiepileptic drugs (AEDs).&#xD;
&#xD;
          7. Patients with a known hypersensitivity to varenicline.&#xD;
&#xD;
          8. Patients with severe concurrent illnesses such as bronchospastic disease,&#xD;
             hyperthyroidism, diabetes mellitus.&#xD;
&#xD;
          9. Patients with known AIDS or other serious illnesses that may require hospitalization&#xD;
             during the study.&#xD;
&#xD;
         10. Female subjects who are pregnant or lactating, or female subjects of child-bearing&#xD;
             potential who are not using acceptable methods of birth control; acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Barrier method (diaphragm or condom) with spermicide&#xD;
&#xD;
               -  Intrauterine progesterone contraceptive system&#xD;
&#xD;
               -  Levonorgesterel implant&#xD;
&#xD;
               -  Medroxyprogesterone acetate contraceptive injection, or&#xD;
&#xD;
               -  Oral contraceptives.&#xD;
&#xD;
         11. Patients with impaired renal function, as indicated by corrected creatinine clearance&#xD;
             below 60 ml/min/70 kg as determined by the modified Cockcroft equation (CDC, 1986).&#xD;
&#xD;
         12. An unacceptable liver panel (liver function tests; LFTs) that may be indicative of&#xD;
             hepatic dysfunction.&#xD;
&#xD;
         13. Clinical laboratory tests (e.g., CBC, blood chemistries, urinalysis) outside normal&#xD;
             limits.&#xD;
&#xD;
         14. History of significant heart disease or dysfunction (e.g., an arrhythmia which&#xD;
             required medication, Wolff Parkinson -White Syndrome, angina pectoris, documented&#xD;
             history of myocardial infarction, heart failure).&#xD;
&#xD;
         15. Electrocardiography (EKG) indicative of 1st degree heart block, sinus tachycardia,&#xD;
             left-axis deviation, non-specific ST or T-wave changes.&#xD;
&#xD;
         16. History of chest pain associated with cocaine use that prompted a visit to a&#xD;
             physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Jennifer Plebani</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

